RMI 10874

RMI 10874 is a tilorone analogue. Tilorone is a small-molecule, orally bioavailable antiviral agent. RMI 10874 completely abolishes lung colonization of an H-2 negative (GR9.B9) MCA-induced fibrosarcoma clone.

Signaling Pathways >> Others >> Others

Research Areas >> Cancer

Research Areas >> Infection

The effect of RMI 10874 (RMI 10,874DA) in the abrogation of the metastatic spread of tumor cells is studied. Pre-treatment of BALB/c mice with the RMI 10,874DA completely eliminates lung colonization of an H-2-negative (GR9.B9) MCA-induced fibrosarcoma clone in an experimental metastasis assay[1]. The effect of a tilorone analogue (RMI 10,874DA) and anti-asialo GM1 serum is studied on the survival of BALB/c and C57B1/6 mice after i.v. injections of different syngeneic murine tumor cells. Natural killer (NK) cell activation in vivo by RMI 10874 prolongs survival and inhibits metastasis formation in mice, even when pretreatment consists of a single dose of the analogue[2]. Tilorone is a small-molecule, orally bioavailable drug that is used clinically as an antiviral[3].

[1]. Algarra I, et al. Generation and control of metastasis in experimental tumor systems; inhibition of experimental metastases by a tilorone analogue. Int J Cancer. 1993 May 28;54(3):518-23.

[2]. Algarra I, et al. Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours. Clin Exp Immunol. 1996 Mar;103(3):499-505.

[3]. Ekins S, et al. Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection. Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01711-17.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline